Are there antihypertensive drugs that have shown par- ticular efficacy in the secondary prevention of IHD? Which antihypertensive drugs should be used in patients who have established CAD with stable angina pectoris, in those with acute coronary syndrome (ACS), which in- cludes unstable angina pectoris (UA), non ST-segment elevation myocardial infarction (NSTEMI), and ST- elevation myocardial infarction (STEMI), and in those with heart failure (HF) caused by CAD? This scientific statement summarizes the published data relating to the treatment of hypertension in the context of Prevention of Cardiovascular Events in Patients With Hypertension and CAD 1380 Antihypertensive Drugs for the Secondary Prevention of Cardiovascular Events in Patients With CAD 1380 Thiazide and Thiazide-Type Diuretics 1380 -Blockers 1380 2.1.3. ACE Inhibitors 1380 Angiotensin Receptor Blockers 1381 2.1.5. Aldosterone Antagonists 1381 Calcium Channel Blockers 1382 Direct Renin Inhibitors 1382 3. BP Goals 1382 Epidemiology and Coronary Physiology 1382 3.1.1. Epidemiological Studies 1382 3.1.2. Coronary Perfusion, Autoregulation, and the J-curve 1382 3.2. Clinical Studies 1383 Lower BP With a Surrogate Outcome 1383 Observational Studies and Clinical Trials 1383 Clinical Trials to Specifically Evaluate Lower BP Goals 1384 Lower BP Goals and Diabetes Mellitus . 1384 Lower BP Goals for the Prevention of Stroke 1385 3.2.6. The Elderly 1385 3.2.7. Conclusions 1385 3.3. Recommendations 1386 Management of Hypertension in Patients With CAD and Stable Angina 1386 4.1. Pharmacological Therapy 1386 -Blockers 1386 Calcium Channel Blockers 1386 4.1.3. ACE Inhibitors 1387 Angiotensin Receptor Blockers 1387 4.1.5. Diuretics 1387 4.1.6. Nitrates 1388 4.2.  Recommendations 1388 Management of Hypertension in Patients With ACS 1388 5.1. Prevalence and Impact on Prognosis 1388 General Principles of BP Management in the Patient With ACS 1389 5.3. Specific Antihypertensive Agents in ACS 1389 5.3.1. Nitroglycerin 1389 -Blockers 1390 Calcium Channel Blockers 1390 5.3.4. 